Literature DB >> 464624

Cancer and scleroderma.

S C Duncan, R K Winkelmann.   

Abstract

Of 2,141 patients with scleroderma who were seen at the Mayo Clinic, Rochester, Minn, between 1959 and 1975, 78 had 87 internal malignancies. The relative frequency of the types of cancers was similar to that for the general population. The increased numbers of patients with breast and uterine carcinomas were consistent with the female preponderance in scleroderma. Contrary to previous reports, carcinoma of the lung was not the most frequent malignancy associated with scleroderma. The lymphoma-leukemia malignancies were second only to breast carcinoma in frequency, comprising about 17% of the malignancies. Both conditions developed within a three-year period in 68% (45/66) of our patients affected with systemic scleroderma, and this subgroup comprised a high mortality group. This study is not an epidemiologic one in the strictest sense, but it is a review of the experience of the Mayo Clinic with patients who have had both scleroderma and an internal malignancy.

Entities:  

Mesh:

Year:  1979        PMID: 464624

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  27 in total

1.  Systemic sclerosis and chronic lymphocytic leukaemia.

Authors:  Y Sidi; R Fadilah; J Pinkhas; M Prokocimer
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

Review 2.  Progressive systemic sclerosis associated with primary small cell carcinoma of the stomach.

Authors:  S Shikuwa; M Senju; H Tanaka; M Kusano; G Matsuda; K Omagari; Y Mizuta; F Takeshima; K Makiyama; M Ito; I Sekine; S Kohno
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

3.  Meigs' syndrome: a rare cause of recurrent pleural effusion in scleroderma.

Authors:  Feng Su; Kristopher W Cummings; Hannah Krigman; Prabha Ranganathan
Journal:  Rheumatol Int       Date:  2012-04-27       Impact factor: 2.631

Review 4.  Management of Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy in a Patient with Scleroderma: Case Report and Review of the Literature.

Authors:  David P Horowitz; Balazs Halmos; John Poneros; Joshua Sonett; Helen Remotti; Ryan J Burri
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 5.  Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications.

Authors:  Ami A Shah; Antony Rosen
Journal:  Curr Opin Rheumatol       Date:  2011-11       Impact factor: 5.006

Review 6.  Cancer and Scleroderma.

Authors:  Emma Weeding; Livia Casciola-Rosen; Ami A Shah
Journal:  Rheum Dis Clin North Am       Date:  2020-06-10       Impact factor: 2.670

7.  Systemic sclerosis following anti-androgenic treatment for prostatic adenocarcinoma.

Authors:  N Giordano; L Magaro; L Fattorini; P Marcucci; E Battisti; A Fioravanti; R Marcolongo
Journal:  Clin Rheumatol       Date:  1993-03       Impact factor: 2.980

8.  Malignancy in scleroderma patients from south west England: a population-based cohort study.

Authors:  Keith Siau; C J Laversuch; P Creamer; K P O'Rourke
Journal:  Rheumatol Int       Date:  2010-01-08       Impact factor: 2.631

Review 9.  Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.

Authors:  Alfred Grassegger; Gabriela Pohla-Gubo; Margret Frauscher; Helmut Hintner
Journal:  Wien Med Wochenschr       Date:  2008

10.  Risk of cancer in patients with scleroderma: a population based cohort study.

Authors:  C L Hill; A-M Nguyen; D Roder; P Roberts-Thomson
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.